ulocuplumab

Ulocuplumab is a fully human IgG4 monoclonal antibody that targets the C-X-C chemokine receptor type 4 (CXCR4). By binding to CXCR4, it blocks the interaction with its ligand stromal derived factor-1 (SDF-1 or CXCL12), thereby inhibiting receptor activation. This disruption of the SDF-1/CXCR4 axis can decrease tumor cell proliferation and migration and induce apoptosis in certain hematologic malignancies such as chronic lymphocytic leukemia (CLL). Ulocuplumab has been investigated primarily for hematologic cancers including multiple myeloma, acute myeloid leukemia, and Waldenstrom's macroglobulinemia. The drug was originally developed by Medarex and later by Bristol Myers Squibb[3][5][8].

Other names

ulocuplumabBMS 936564BMS936564BMS-936564MDX-1338MDX1338MDX 1338